ketoconazole has been researched along with Familial Precocious Puberty in 22 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Infantile Cushing's syndrome is potentially found as part of McCune-Albright syndrome (MAS) which is caused by postzygotic somatic mutations of the GNAS gene." | 1.51 | A Novel GNAS Mutation Causing Isolated Infantile Cushing's Syndrome. ( Dejkhamron, P; Ittiwut, C; Natesirinilkul, R; Shotelersuk, V; Sunkonkit, K; Suphapeetiporn, K; TangNgam, H, 2019) |
| "Ketoconazole treatment decreased circulating testosterone in childhood, supported by experimental suppression of testosterone production in his adult testis tissue cultured ex vivo." | 1.46 | Germ Cell Neoplasia in Situ and Preserved Fertility Despite Suppressed Gonadotropins in a Patient With Testotoxicosis. ( Blomberg Jensen, M; Christiansen, P; Frederiksen, H; Grønkær Toft, B; Juel Mortensen, L; Juul, A; Jørgensen, A; Loya, AC; Nielsen, JE; Rajpert-De Meyts, E; Rønholt, AM; Skakkebæk, NE, 2017) |
| "Testotoxicosis is a rare disorder which presents as isosexual peripheral precocious puberty in males." | 1.42 | Testotoxicosis: Report of Two Cases, One with a Novel Mutation in LHCGR Gene. ( Büyükünal, C; Ceylaner, S; Ercan, O; Evliyaoğlu, O; Özcabı, B; Özcan, R; Tahmiscioğlu Bucak, F; Tüysüz, B, 2015) |
| "Familial male-limited precocious puberty (FMPP) or testotoxicosis is a rare gonadotrophin-independent form of sexual precocity caused by constitutively activating mutations of the LH receptor." | 1.35 | Long-term treatment of familial male-limited precocious puberty (testotoxicosis) with cyproterone acetate or ketoconazole. ( Almeida, MQ; Antonini, SR; Arnhold, IJ; Brito, VN; de Castro, M; Guerra-Junior, G; Latronico, AC; Lins, TS; Mendonca, BB, 2008) |
| "Familial male-limited precocious puberty is a rare cause of precocious puberty due to activating mutations of the LH receptor, leading to early onset virilization and short stature." | 1.33 | Adult height after ketoconazole treatment in patients with familial male-limited precocious puberty. ( Carel, JC; Chaussain, JL; Chauvet, G; Lahlou, N; Roger, M; Soriano-Guillén, L, 2005) |
| "Familial male-limited precocious puberty is a dominant autosomal genetic disease caused by activating LH receptor gene mutations, clinically expressed only in males." | 1.33 | Activating mutations in the luteinizing hormone receptor gene: a human model of non-follicle-stimulating hormone-dependent inhibin production and germ cell maturation. ( Barbet, P; Carel, JC; Lahlou, N; Mitchell, V; Roger, M; Soriano-Guillen, L, 2006) |
| "Ketoconazole was reintroduced cautiously at a lower dose, with no ill-effect, and reasonable control of testotoxicosis." | 1.29 | Hazards of ketoconazole therapy in testotoxicosis. ( Babovic-Vuksanovic, D; Donaldson, MD; Gibson, NA; Wallace, AM, 1994) |
| "All types of precocious puberty are characterized by rapid growth and advancement of skeletal age, leading to the paradox of the tall child becoming a short adult as a result of premature epiphyseal fusion." | 1.28 | Diagnosis and management of precocious puberty. ( Styne, DM; Wheeler, MD, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (27.27) | 18.7374 |
| 1990's | 8 (36.36) | 18.2507 |
| 2000's | 4 (18.18) | 29.6817 |
| 2010's | 3 (13.64) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| García García, E | 1 |
| Álvarez Del Vayo, C | 1 |
| Castaño, L | 1 |
| Juel Mortensen, L | 1 |
| Blomberg Jensen, M | 1 |
| Christiansen, P | 1 |
| Rønholt, AM | 1 |
| Jørgensen, A | 1 |
| Frederiksen, H | 1 |
| Nielsen, JE | 1 |
| Loya, AC | 1 |
| Grønkær Toft, B | 1 |
| Skakkebæk, NE | 1 |
| Rajpert-De Meyts, E | 1 |
| Juul, A | 1 |
| Dejkhamron, P | 1 |
| Ittiwut, C | 1 |
| TangNgam, H | 1 |
| Sunkonkit, K | 1 |
| Natesirinilkul, R | 1 |
| Suphapeetiporn, K | 1 |
| Shotelersuk, V | 1 |
| Özcabı, B | 1 |
| Tahmiscioğlu Bucak, F | 1 |
| Ceylaner, S | 1 |
| Özcan, R | 1 |
| Büyükünal, C | 1 |
| Ercan, O | 1 |
| Tüysüz, B | 1 |
| Evliyaoğlu, O | 1 |
| Messina, MF | 1 |
| Arrigo, T | 1 |
| Wasniewska, M | 1 |
| Lombardo, F | 1 |
| Crisafulli, G | 1 |
| Salzano, G | 1 |
| De Luca, F | 1 |
| Soriano-Guillén, L | 2 |
| Lahlou, N | 2 |
| Chauvet, G | 1 |
| Roger, M | 2 |
| Chaussain, JL | 1 |
| Carel, JC | 2 |
| Mitchell, V | 1 |
| Barbet, P | 1 |
| Almeida, MQ | 1 |
| Brito, VN | 1 |
| Lins, TS | 1 |
| Guerra-Junior, G | 1 |
| de Castro, M | 1 |
| Antonini, SR | 1 |
| Arnhold, IJ | 1 |
| Mendonca, BB | 1 |
| Latronico, AC | 1 |
| Feuillan, PP | 1 |
| Laue, L | 1 |
| Cutler, GB | 1 |
| Kulin, HE | 1 |
| Bourguignon, JP | 1 |
| Babovic-Vuksanovic, D | 1 |
| Donaldson, MD | 1 |
| Gibson, NA | 1 |
| Wallace, AM | 1 |
| Bertelloni, S | 1 |
| Baroncelli, GI | 1 |
| Lala, R | 1 |
| Cappa, M | 1 |
| Matarazzo, P | 1 |
| De Sanctis, C | 1 |
| Saggese, G | 1 |
| Cassorla, FG | 1 |
| Wheeler, MD | 2 |
| Styne, DM | 2 |
| Holland, FJ | 2 |
| Fishman, L | 1 |
| Bailey, JD | 1 |
| Fazekas, AT | 1 |
| Root, AW | 1 |
| Zamanillo, J | 1 |
| Duckett, G | 1 |
| Sweetland, M | 1 |
| Sonino, N | 1 |
| Kirsch, SE | 1 |
| Selby, R | 1 |
| Kelch, RP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mechanisms of Control of the Intratesticular Hormonal Milieu in Man[NCT01215292] | Phase 1/Phase 2 | 46 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01215292)
Timeframe: 10 days
| Intervention | ng/mL (Median) |
|---|---|
| Acyline + Testosterone Gel (Tgel)+ Placebo | .87 |
| Acyline + Tgel + Ketoconazole 400mg | 0.5 |
| Acyline + Tgel + Ketoconazole 800mg | 0.12 |
| Acyline & TGel & Dutasteride 2.5mg | 1.7 |
| Acyline & TGel & Anastrazole 1mg | 3.6 |
(NCT01215292)
Timeframe: 10 days
| Intervention | ng/mL (Median) |
|---|---|
| Acyline + Testosterone Gel (Tgel)+ Placebo | 3.17 |
| Acyline & TGel & Ketoconazole 400 mg | 2.08 |
| Acyline & TGel & Ketoconazole 800 mg | 1.46 |
| Acyline & TGel & Dutasteride | 0.12 |
| Acyline & TGel & Anastrazole | 3.63 |
(NCT01215292)
Timeframe: 10 days
| Intervention | ng/mL (Median) |
|---|---|
| Acyline + Testosterone Gel + Placebo | 14 |
| Acyline + Tgel + Ketoconazole 400mg | 3.7 |
| Acyline + Tgel + Ketoconazole 800mg | 1.7 |
| Acyline & TGel & Dutasteride 2.5mg | 18.4 |
| Acyline & TGel & Anastrazole 1mg | 24.0 |
4 reviews available for ketoconazole and Familial Precocious Puberty
| Article | Year |
|---|---|
[Concept and therapeutic management of precocious puberty].
Topics: Adolescent; Body Height; Bone Development; Child; Female; Growth; Growth Inhibitors; Humans; Ketocon | 1991 |
The treatment of precocious puberty.
Topics: Androgen Antagonists; Delayed-Action Preparations; Female; Gonadotropin-Releasing Hormone; Humans; K | 1991 |
[The antimycotic ketoconazole. Indications in prostate disease, hirsutism, precocious puberty and Cushing syndrome?].
Topics: Cushing Syndrome; Hirsutism; Humans; Ketoconazole; Male; Prostatic Diseases; Puberty, Precocious | 1988 |
The endocrine effects of ketoconazole.
Topics: Animals; Breast Neoplasms; Cushing Syndrome; Endocrine System Diseases; Female; Hirsutism; Humans; K | 1986 |
18 other studies available for ketoconazole and Familial Precocious Puberty
| Article | Year |
|---|---|
Familial male-limited precocious puberty (testotoxicosis): Usefulness of treatment with ketoconazole and triptorelin.
Topics: Gonadotropin-Releasing Hormone; Humans; Ketoconazole; Male; Puberty, Precocious; Triptorelin Pamoate | 2022 |
Germ Cell Neoplasia in Situ and Preserved Fertility Despite Suppressed Gonadotropins in a Patient With Testotoxicosis.
Topics: Adult; Body Composition; Body Height; Bone and Bones; Fertility; Gonadotropins; Hormone Antagonists; | 2017 |
A Novel GNAS Mutation Causing Isolated Infantile Cushing's Syndrome.
Topics: Chromogranins; Cushing Syndrome; Exome Sequencing; Female; Fibrous Dysplasia, Polyostotic; GTP-Bindi | 2019 |
Testotoxicosis: Report of Two Cases, One with a Novel Mutation in LHCGR Gene.
Topics: Anastrozole; Androgen Antagonists; Anilides; Aromatase Inhibitors; Cytochrome P-450 CYP3A Inhibitors | 2015 |
Combined treatment with ketoconazole and cyproterone acetate in a boy with McCune-Albright syndrome and peripheral precocious puberty.
Topics: Androgen Antagonists; Antifungal Agents; Child, Preschool; Cyproterone Acetate; Fibrous Dysplasia, P | 2008 |
Adult height after ketoconazole treatment in patients with familial male-limited precocious puberty.
Topics: Adult; Age Determination by Skeleton; Body Height; Child; Child, Preschool; Follow-Up Studies; Human | 2005 |
Activating mutations in the luteinizing hormone receptor gene: a human model of non-follicle-stimulating hormone-dependent inhibin production and germ cell maturation.
Topics: Anti-Mullerian Hormone; Biopsy; Child; Child, Preschool; Follicle Stimulating Hormone; Germ Cells; G | 2006 |
Long-term treatment of familial male-limited precocious puberty (testotoxicosis) with cyproterone acetate or ketoconazole.
Topics: Adolescent; Androgen Antagonists; Body Height; Child; Child, Preschool; Cyproterone Acetate; Follow- | 2008 |
McCune-Albright syndrome.
Topics: Adolescent; Calcitriol; Diagnosis, Differential; Female; Fibrous Dysplasia, Polyostotic; Humans; Ket | 1994 |
Familial male precocious puberty.
Topics: Child; Gonadotropin-Releasing Hormone; Humans; Ketoconazole; Male; Puberty, Precocious; Spironolacto | 1994 |
True or central precocious puberty.
Topics: Cyproterone Acetate; Female; Gonadotropin-Releasing Hormone; Humans; Ketoconazole; Male; Medroxyprog | 1994 |
Hazards of ketoconazole therapy in testotoxicosis.
Topics: Child; Dose-Response Relationship, Drug; Drug Hypersensitivity; Humans; Hyperplasia; Ketoconazole; L | 1994 |
Long-term outcome of male-limited gonadotropin-independent precocious puberty.
Topics: Androgen Antagonists; Buserelin; Child; Child, Preschool; Cyproterone Acetate; Drug Therapy, Combina | 1997 |
Diagnosis and management of precocious puberty.
Topics: Child; Child, Preschool; Diagnosis, Differential; Female; Gonadotropin-Releasing Hormone; Humans; Ke | 1990 |
Ketoconazole in the management of precocious puberty not responsive to LHRH-analogue therapy.
Topics: 17-alpha-Hydroxyprogesterone; Adrenocorticotropic Hormone; Buserelin; Child Behavior; Child, Prescho | 1985 |
Gonadotropin-independent isosexual precocity in a boy with tuberous sclerosis: effect of ketoconazole.
Topics: Age Determination by Skeleton; Child, Preschool; Follicle Stimulating Hormone; Gonadotropins, Pituit | 1986 |
Gonadotropin-independent precocious puberty ("testotoxicosis"): influence of maturational status on response to ketoconazole.
Topics: Child; Child, Preschool; Chorionic Gonadotropin; Gonadotropin-Releasing Hormone; Humans; Hydrocortis | 1987 |
Management of precocious puberty.
Topics: Child; Female; Humans; Ketoconazole; Male; Puberty, Precocious | 1985 |